capital raise

AIM ImmunoTech closes $1.8M rights offering to advance Ampligen immunotherapy development for late-stage pancreatic cancer treatment.

Maris-Tech raises $2M through registered direct offering of shares at $1.24, deploying capital for working capital and corporate operations.

First Atlantic Nickel closes $3.9M final funding round at $0.18/share, with strategic investor maintaining 9.9% stake to fund nickel exploration projects.

Battalion Oil surges 15.79% after-hours on Iran tensions and announces $15M private placement at $5.50 per share.

AST SpaceMobile stock plunged 28.8% in February after raising $1 billion via convertible notes, as investors questioned its $35.4 billion valuation for a pre-revenue, money-losing company.

Dave Inc. prices $175M convertible notes at 0% with 32.5% conversion premium, plans $70.5M share buyback using proceeds.

MAIA Biotechnology closes $30M public offering of 20M shares at $1.50/share, funding clinical trials and operations.

AIM ImmunoTech raises $1.8M through rights offering expiring March 3, 2026, providing working capital for ongoing immunotherapy operations.

MAIA Biotechnology prices $30M public offering at $1.50/share to fund clinical trials. Offering closes March 4, 2026.

Palvella Therapeutics closed $230M public offering at $125/share on February 27, 2026, fully exercising underwriter options to fund rare skin disease programs.

Duos Technologies raises $65M through stock offering to expand its Edge Data Center business segment amid strong 288% revenue growth.

Anteris secures $320M funding to advance DurAVR heart valve through global trials, with FDA approval and increased clinical development spending.

Bicara Therapeutics raises $172.5M in oversubscribed offering, with proceeds funding development of lead immunotherapy candidate ficerafusp alfa for solid tumors.

Thesis Gold raises C$44M from AngloGold Ashanti and Centerra Gold to advance its Lawyers-Ranch gold-silver project in British Columbia.

Brainstorm Cell Therapeutics raised $2M in February through private placement at $0.60/share. Funds support general operations, regulatory work, and Phase 3b trial preparations for ALS therapy NurOwn.

Larimar Therapeutics raises $100M through expanded share offering at $5 per share, funding development of lead drug candidate nomlabofusp and operations.

Larimar Therapeutics raises $100M through expanded public offering at $5 per share, funding clinical development of rare disease therapeutic candidate nomlabofusp.

Draganfly raises $50M through registered direct offering at $7 per share. Funds will support product development, R&D, and potential strategic acquisitions.

Palvella Therapeutics raised $200M through upsized share offering to fund clinical development of rare disease therapies including skin disease and vascular malformation treatments.

Ideal Power raised $14M to commercialize its B-TRAN semiconductor technology, funding customer design-ins, partnerships, and production infrastructure.